We are live on ! Find out more
PACB icon

Pacific Biosciences
PACB

236 hedge funds and large institutions have $1.83B invested in Pacific Biosciences in 2022 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 65 increasing their positions, 77 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

69% more call options, than puts

Call options by funds: $24.6M | Put options by funds: $14.5M

49% more capital invested

Capital invested by funds: $1.23B → $1.83B (+$598M)

48% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 29

5.23% more ownership

Funds ownership: 94.23% → 99.45% (+5.2%)

4% more funds holding

Funds holding: 227 → 236 (+9)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

16% less repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 77

Holders
236
Holders Change
+9
Holders Change %
+3.96%
% of All Funds
3.79%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
43
Increased
65
Reduced
77
Closed
29
Calls
$24.6M
Puts
$14.5M
Net Calls
+$10.1M
Net Calls Change
+$18.4M

Top Buyers

Rank Fund Capital Flow
1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$36.3M
2
FCM
Farallon Capital Management
California
+$34.5M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$24.1M
4
Ameriprise
Ameriprise
Minnesota
+$13.6M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$9.46M

Top Sellers

Rank Fund Capital Flow
1
JSP
Jackson Square Partners
California
-$45.3M
2
AIM
ARK Investment Management
Florida
-$25.9M
3
Capital International Investors
Capital International Investors
California
-$20.2M
4
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$12.9M
5
DM
Deerfield Management
New York
-$11.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
DCM
251
Dupont Capital Management
Delaware
– -$115K -19,808 Closed
AWA
252
Arete Wealth Advisors
Illinois
– -$87K -15,042 Closed
BFM
253
Boothbay Fund Management
New York
– -$83K -14,283 Closed
TSS
254
Two Sigma Securities
New York
– -$81K -13,908 Closed
DCM
255
Difesa Capital Management
New York
– -$70K -12,000 Closed
IA
256
Inspire Advisors
Idaho
– -$64K -11,000 Closed
GWM
257
Greenwich Wealth Management
Connecticut
– -$16K -10,200 Closed
BAM
258
Byrne Asset Management
New Jersey
– -$30K -5,140 Closed
HI
259
Hudock Inc
Pennsylvania
– -$23K -4,063 Closed
CWM
260
Castle Wealth Management
Florida
– -$12K -2,000 Closed
TWC
261
TD Waterhouse Canada
Ontario, Canada
– -$5.82K -1,000 Closed
MCA
262
Maryland Capital Advisors
Maryland
– -$1K -199 Closed
C
263
Covestor
United Kingdom
– -$17 -2 -8%
CAL
264
Capital Advisors Ltd
Ohio
– +$112 +13 New
7 8 9 10
11

PACB Hedge Fund Activity: Q4 2022 in Review

236 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q4 2022, worth a combined $1.83B — up 49% from $1.23B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new PACB positions and 29 closed out — a net gain of 14 holders — while 65 added to existing stakes and 77 trimmed.

The largest buyer was Lord, Abbett & Co, opening a new position worth an estimated $36.3M. The largest seller was Jackson Square Partners, cutting an estimated $45.3M.

  • 236 institutional investors held Pacific Biosciences (PACB) as of Q4 2022, up from 227 in Q3 2022.
  • Funds reported $1.83B of Pacific Biosciences stock for Q4 2022, up 49% quarter-over-quarter.
  • 43 funds opened new Pacific Biosciences positions in Q4 2022 and 29 closed out, a net change of +14 holders.
  • The largest Pacific Biosciences buyer in Q4 2022 was Lord, Abbett & Co, an estimated $36.3M added.
  • The largest Pacific Biosciences seller in Q4 2022 was Jackson Square Partners, an estimated $45.3M sold.

Based on aggregated 13F filings for Q4 2022.